M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 9 of 54
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT05056818
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
NCT04693468
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study
NCT04783168
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
NCT04615013
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
NCT04678427
The Impact of COVID-19 on Pulmonary Procedures
NCT05022446
Role of Diet on the Microbiome of the Digestive System
NCT04666727
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
NCT04555577
The Rise in Robotic Atypical Segmentectomies
NCT04644952
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
NCT04604522
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
NCT04505254
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
NCT04239157
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
NCT04984551
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
NCT04988009
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
NCT04589624
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
NCT04796818
Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation
NCT06840262
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
NCT04169763
Expressive Writing for the Management of Stress in Cancer Survivors
NCT04776941
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT04575935
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
NCT04604509
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
NCT04565665
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04169737
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT04090567
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
NCT04493138
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
NCT02962661
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
NCT04551378
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
NCT04560673
Survey of Current Interventional and Diagnostic Imaging Residents After Participation in Endovascular Simulator Training
NCT04832698
Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines
NCT04595422
Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia
NCT04533919
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
NCT04474301
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT04216524
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
NCT04128748
Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce
NCT04491292
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT05054296
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
NCT04373720
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
NCT04022239
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
NCT04623931
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
NCT04216732
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
NCT05011045
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT04140487
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
NCT04739072
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04047641
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT03968406
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT03911388
Patient-Specific Computational Walking Models in Improving Surgical and Rehabilitation Treatment in Patients With Pelvic Sarcomas
NCT05054335
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
NCT05049538
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04054167
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
NCT04479696
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.